Shots:

• The CHMP recommendation for approval in EU is based on LIBERTY AD program including P-III study & an open-label ext. study assessing Dupixent in adolescents aged 12-17 yrs. with uncontrolled AD
• Post-approval- Dupixent will be the first biologic to be approved in the EU for the treatment of AD with its expected EMA’s decision in coming months
• Dupixent is a mAb targeting IL-4 & IL-13 and has received approval in the multiple countries including the US- EU and Japan for mod. to sev. AD and asthma

Click here to read full press release/ article | Ref: Sanofi | Image: Arabian Business